OncoMatch/Breast Cancer/ESR1 (ER)
Breast CancerESR1 (ER) Clinical Trials
Estrogen receptor (ER) expression defines hormone receptor-positive breast cancer — approximately 75% of cases — and determines eligibility for endocrine therapy. Acquired ESR1 mutations arise in metastatic ER+ disease after aromatase inhibitor exposure and confer resistance. Trials test selective estrogen receptor degraders (SERDs) including elacestrant (FDA-approved for ESR1-mutant disease), CDK4/6 inhibitor combinations, and novel ESR1-targeting agents.
Top recruiting ESR1 (ER) Breast Cancer trials
Ranked by phase and US site count.
See all trials matched to your profile →Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NRG Oncology
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
NRG Oncology
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Gilead Sciences
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Stemline Therapeutics, Inc.
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
AstraZeneca
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Eli Lilly and Company
More ESR1 (ER) Breast Cancer trials
See all in search →10 international trials (no US sites)
Browse other molecular targets with active Breast Cancer trials.